BioCardia, Inc. (NASDAQ:BCDA) Sees Large Growth in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 86,300 shares, an increase of 72.6% from the October 15th total of 50,000 shares. Based on an average daily volume of 831,300 shares, the short-interest ratio is currently 0.1 days. Currently, 3.2% of the shares of the stock are sold short.

BioCardia Stock Down 2.1 %

Shares of NASDAQ BCDA opened at $2.35 on Thursday. The stock’s fifty day simple moving average is $2.60 and its 200 day simple moving average is $3.37. The stock has a market capitalization of $4.98 million, a price-to-earnings ratio of -0.44 and a beta of 1.28. BioCardia has a 52-week low of $1.96 and a 52-week high of $23.25.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). As a group, analysts anticipate that BioCardia will post -5.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research report on Monday, October 28th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.